Advancing Together and Moving Forward: Combination Gene and Cellular Immunotherapies

Overview

Journal Mol Ther Oncolytics

Publisher Cell Press

Date 2022 Jun 13

PMID 35694448

Authors

Saul J Priceman

Waseem Cheema

Prasad S Adusumilli

Affiliations

Soon will be listed here.

Citing Articles

Identification of Prognostic and Predictive Biomarkers and Druggable Targets among 205 Antioxidant Genes in 21 Different Tumor Types via Data-Mining.

Ozenver N, Efferth T Pharmaceutics. 2023; 15(2).

PMID: 36839749 PMC: 9959161. DOI: 10.3390/pharmaceutics15020427.

Next-generation immunotherapy for solid tumors: combination immunotherapy with crosstalk blockade of TGFβ and PD-1/PD-L1.

Quach H, Hou Z, Bellis R, Saini J, Amador-Molina A, Adusumilli P Expert Opin Investig Drugs. 2022; 31(11):1187-1202.

PMID: 36448335 PMC: 10085570. DOI: 10.1080/13543784.2022.2152323.

References

Poggi A, Zocchi M . Natural killer cells and immune-checkpoint inhibitor therapy: Current knowledge and new challenges. Mol Ther Oncolytics. 2022; 24:26-42. PMC: 8693432. DOI: 10.1016/j.omto.2021.11.016. View

McAusland T, van Vloten J, Santry L, Guilleman M, Rghei A, Ferreira E . Combining vanadyl sulfate with Newcastle disease virus potentiates rapid innate immune-mediated regression with curative potential in murine cancer models. Mol Ther Oncolytics. 2021; 20:306-324. PMC: 7868934. DOI: 10.1016/j.omto.2021.01.009. View

Liu W, Dai E, Liu Z, Ma C, Guo Z, Bartlett D . Therapeutic Cancer Vaccination with an Oncolytic Virus Expressing Membrane-Tethered IL-2. Mol Ther Oncolytics. 2020; 17:350-360. PMC: 7210382. DOI: 10.1016/j.omto.2020.04.006. View

Zhang Y, Qian L, Chen K, Gu S, Wang J, Meng Z . Intraperitoneal oncolytic virotherapy for patients with malignant ascites: Characterization of clinical efficacy and antitumor immune response. Mol Ther Oncolytics. 2022; 25:31-42. PMC: 8971678. DOI: 10.1016/j.omto.2022.03.003. View

Cherkassky L, Hou Z, Amador-Molina A, Adusumilli P . Regional CAR T cell therapy: An ignition key for systemic immunity in solid tumors. Cancer Cell. 2022; 40(6):569-574. PMC: 9197990. DOI: 10.1016/j.ccell.2022.04.006. View

Annels N, Simpson G, Denyer M, Arif M, Coffey M, Melcher A . Oncolytic Reovirus-Mediated Recruitment of Early Innate Immune Responses Reverses Immunotherapy Resistance in Prostate Tumors. Mol Ther Oncolytics. 2021; 20:434-446. PMC: 7900644. DOI: 10.1016/j.omto.2020.09.010. View

Alzubi J, Dettmer-Monaco V, Kuehle J, Thorausch N, Seidl M, Taromi S . PSMA-Directed CAR T Cells Combined with Low-Dose Docetaxel Treatment Induce Tumor Regression in a Prostate Cancer Xenograft Model. Mol Ther Oncolytics. 2020; 18:226-235. PMC: 7372156. DOI: 10.1016/j.omto.2020.06.014. View

Veinalde R, Pidelaserra-Marti G, Moulin C, Jeworowski L, Kuther L, Buchholz C . Oncolytic measles vaccines encoding PD-1 and PD-L1 checkpoint blocking antibodies to increase tumor-specific T cell memory. Mol Ther Oncolytics. 2022; 24:43-58. PMC: 8693420. DOI: 10.1016/j.omto.2021.11.020. View

Priceman S, Forman S, Brown C . Smart CARs engineered for cancer immunotherapy. Curr Opin Oncol. 2015; 27(6):466-74. PMC: 4659816. DOI: 10.1097/CCO.0000000000000232. View

10.

Fabian K, Hodge J . The emerging role of off-the-shelf engineered natural killer cells in targeted cancer immunotherapy. Mol Ther Oncolytics. 2021; 23:266-276. PMC: 8560822. DOI: 10.1016/j.omto.2021.10.001. View

11.

Martikainen M, Ramachandran M, Lugano R, Ma J, Martikainen M, Dimberg A . IFN-I-tolerant oncolytic Semliki Forest virus in combination with anti-PD1 enhances T cell response against mouse glioma. Mol Ther Oncolytics. 2021; 21:37-46. PMC: 8042242. DOI: 10.1016/j.omto.2021.03.008. View

12.

Scherwitzl I, Opp S, Hurtado A, Pampeno C, Loomis C, Kannan K . Sindbis Virus with Anti-OX40 Overcomes the Immunosuppressive Tumor Microenvironment of Low-Immunogenic Tumors. Mol Ther Oncolytics. 2020; 17:431-447. PMC: 7251545. DOI: 10.1016/j.omto.2020.04.012. View

13.

Kankeu Fonkoua L, Sirpilla O, Sakemura R, Siegler E, Kenderian S . CAR T cell therapy and the tumor microenvironment: Current challenges and opportunities. Mol Ther Oncolytics. 2022; 25:69-77. PMC: 8980704. DOI: 10.1016/j.omto.2022.03.009. View

14.

Cervera-Carrascon V, Quixabeira D, Havunen R, Santos J, Kutvonen E, Clubb J . Comparison of Clinically Relevant Oncolytic Virus Platforms for Enhancing T Cell Therapy of Solid Tumors. Mol Ther Oncolytics. 2020; 17:47-60. PMC: 7163046. DOI: 10.1016/j.omto.2020.03.003. View

15.

Chai D, Qiu D, Shi X, Ding J, Jiang N, Zhang Z . Dual-targeting vaccine of FGL1/CAIX exhibits potent anti-tumor activity by activating DC-mediated multi-functional CD8 T cell immunity. Mol Ther Oncolytics. 2022; 24:1-13. PMC: 8688948. DOI: 10.1016/j.omto.2021.11.017. View

16.

Biegert G, Rosewell Shaw A, Suzuki M . Current development in adenoviral vectors for cancer immunotherapy. Mol Ther Oncolytics. 2021; 23:571-581. PMC: 8660697. DOI: 10.1016/j.omto.2021.11.014. View

17.

Zhang Y, Liu C, Wang T, Kong F, Zhang H, Yi J . Therapeutic effects of mesenchymal stem cells loaded with oncolytic adenovirus carrying decorin on a breast cancer lung metastatic mouse model. Mol Ther Oncolytics. 2022; 24:486-496. PMC: 8850566. DOI: 10.1016/j.omto.2022.01.007. View

18.

Yeo D, Giardina C, Saxena P, Rasko J . The next wave of cellular immunotherapies in pancreatic cancer. Mol Ther Oncolytics. 2022; 24:561-576. PMC: 8857655. DOI: 10.1016/j.omto.2022.01.010. View

19.

Morello A, Sadelain M, Adusumilli P . Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors. Cancer Discov. 2015; 6(2):133-46. PMC: 4744527. DOI: 10.1158/2159-8290.CD-15-0583. View

20.

Wenthe J, Naseri S, Hellstrom A, Moreno R, Ullenhag G, Alemany R . Immune priming using DC- and T cell-targeting gene therapy sensitizes both treated and distant B16 tumors to checkpoint inhibition. Mol Ther Oncolytics. 2022; 24:429-442. PMC: 8810301. DOI: 10.1016/j.omto.2022.01.003. View